In addition to the opportunities coming from the increasing number of clinical trials focusing on tumours with DDR defects [41], knowledge of a mutation in this pathway would give patients a potential therapeutic option that would otherwise be lost if overly restrictive eligibility criteria (i.e. based on familial history) excluded such mutated cases from testing or if the analysis were limited to BRCA1 and BRCA2. Indeed, up to 25% of PCs harbour actionable molecular alterations, the majority of which are in the DDR pathway [45]. The gene discussed is BRCA1; the disease is neoplasm.